Comparison of busulphan, hydroxyurea and allogeneic bone marrow transplantation (BMT) in chronic myeloid leukaemia: BMT prolongs survival

Hematology Journal

Volumn 5, Issue 6, 2004, Pages 462-466

  Olsson Strömberg, Ulla ^a   Simonsson, Bengt ^a   Ahlgren, Tomas ^b   Björkholm, Magnus ^c   Carlsson, Karin ^d   Gahrton, Gösta ^c   Hast, Robert ^c   Löfvenberg, Eva ^e   Linder, Olle ^f   Ljungman, Per ^c   Malm, Claes ^d   Paul, Christer ^c   Rödjer, Stig ^g   Turesson, Ingemar ^b   Udén, Ann Mari ^c   Wahlin, Anders ^e   Killander, Andreas ^a   Wadman, Bengt ^f   Westin, Jan ^g   Vikrot, Olle ^f   Zettervall, Olle ^b   Öberg, Gunnar ^a   more..

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^e UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^f ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^g SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Bone marrow transplantation; Busulphan; Chronic myeloid leukaemia; Hydroxyurea; Randomised

Indexed keywords

BUSULFAN; HYDROXYUREA;

ADOLESCENT; ADULT; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BLAST TRANSFORMATION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG INTERMITTENT THERAPY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; STATISTICAL ANALYSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BONE MARROW TRANSPLANTATION; BUSULFAN; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYDROXYUREA; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 19944406090     PISSN: 14664860     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.thj.6200552     Document Type: Article

References (24)

1. McGlave P, Kollman, Shu XO, Anasetti C, Nademanee A, Champlin R et al. The first 1000 unrelated donor transplants for CML lessons from the National Marrow Donor Program (NMDP) experience. Blood 1996; 88: 485a (abstract 1922).
2. Chronic Myeloid Leukemia Trialists Collaborative Group. Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials. J Nat Cancer Inst 1997; 89: 1616-1620.
3. The Benelux CML Study Group. Randomized study on hydroxyurea alone versus hydroxyurea combined with low-dose interferon-α 2 b for chronic myeloid leukemia. Blood 1998; 91: 2713-2721.
4. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Long-term follow up of the Italian trial of interferon - alpha versus conventional chemotherapy in chronic myeloid leukemia. Blood 1998; 92: 1541-1548.
5. Simonsson B, Oberg G, Bjoreman M, Bjorkholm M, Carneskog J, Gahrton G et al. Intensive treatment in order to minimize the Ph-positive clone in CML. Bone Marrow Transplant 1996 (Suppl 3): S63-S64.
6. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346: 645-652.
7. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994-1004.
8. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passer C, Guilhot F et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase in chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99: 1928-1937.
9. Haut A, Abbott WS, Wintrobe MM, Cartwright GE. Busulfan in the treatment of chronic myelocytic leukaemia. The effect of long terms intermittent therapy. Blood 1961; 17: 1-19.
10. Najean Y, Rain J-D, Dresch C, Gogul A, Lejeune F, Echard M et al. Risk of leukemia carcinoma and myelofibros is in chemotherapy treated patients with polycytemia vera. Leukemia Lymphoma 1996; 22 (Suppl 1): 111-119.
11. Bolin RW, Robinson WA, Sutherland J, Hamman RF. Busulfan versus hydroxyurea in long-term therapy of chronic myelogenous leukemia. Cancer 1982; 50: 1683-1686.
12. Chronic Myeloid Leukemia Trialists Collaborative Group. Hydroxyurea versus busulphan for chronic myeloid leukaemia: an individual patient data meta-analysis of three randomized trials. Br J Haematol 2000; 110: 573-576.
13. Kaplan EL, Meier P. Non-parametric estimation from incomplete observation. J Am Stat Assoc (B) 1958; 53: 457-481.
14. Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE and the Italian Study Group. Prognostic discrimination in 'good risk' chronic granulocytic leukemia. Blood 1984; 63: 789-799.
15. Sokal JE, Baccarani M, Tura S, Fiacchini M, Cervantes F, Rozman C et al. Prognostic discrimination among younger patients with chronic granulocytic leukemia: relevance to bone marrow transplantation. Blood 1985; 66: 1352-1357.
16. Allan NC, Richards SM, Shepherd PCA. UK Medical Research Council. Randomised multicentre trial of interferon-1 for chronic myeloid leukemia: improved survival irrespective of cytogenetic response. Lancet 1995; 345: 1392-1397.
17. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, et al., The German CML Study Group. Randomized comparison of busulphan and hydroxyurea in CML prolongation of survival by hydroxyurea. Blood 1993; 82: 398-407.
18. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK et al. Randomized comparison of interferon - α with busulphan and hydroxyurea in chronic myelogenous leukaemia. The German CML Study Group. Blood 1994; 84: 4064-4077.
19. Clift RA, Appelbaum FR, Thomas ED. Treatment of chronic myeloid leukemia by marrow transplantation. Blood 1993; 82: 1954-1956.
20. Gratwohl A, Hermans J, Niederwieser D, Frassoni F, Arcese W, Gahrton G et al. Bone marrow transplantation for chronic myeloid leukemia: long term results. Chronic Leukemia Working Party of the European Group for Bone Marrow Transplantation. Bone Marrow Transplantation 1993; 12: 509-516.
21. Van Rhee F, Szydlo RM, Hermans J, Devergie A, Frassoni F, Arcese W et al. Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1997; 20: 553-560.
22. Gale RP, Hehlmann R, Zhang MJ, Hasford J, Goldman JM, Heimpel H et al. Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukaemia. The German CML Study Group. Blood 1998; 91: 1810-1819.
23. Guilhot F, Chastang C, Michallet M, Guerci A, Harousseau JL, Maloisel F et al. Interferon alfa -2 b combined with cytarabine versus interferon alone in chronic myelogenous leukaemia. French Chronic Myeloid Leukemia Study Group. New Eng J Med 1997; 337: 223-229.
24. Hansen JA, Gooley TA, Martin PJ, Appelbaum F, Chauncey TR, Clift RA et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. New Engl J Med 1998; 338: 962-968.